New article published in Open Forum of Infectious Diseases co-authored by SPECTRE’s Dr. Corri Levine: Appropriate representation is vital when conducting clinical trials and this is just as important during emerging infectious disease outbreaks. The Adaptive COVID-19 Treatment Trial (ACTT) was one of the first trials to test therapeutics against COVID-19, initiated early in the pandemic when very little was known about the disease and susceptible populations. This paper used ACTT as a model for selecting appropriate comparators when evaluating trial representation.